At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 80 target
Drug / intervention
Maraviroc +1 moredrug
Likely dose
Maraviroc 300mgfrom record
Key inclusion· 7
- ✓Age 18 years or older at consent
- ✓Acute ischemic stroke
- ✓Stroke onset less than 7 days before randomization
- ✓Contralateral, unilateral, incomplete upper limb paresis
Key exclusion· 11
- ✕Pregnancy or lactation, or positive pregnancy test in women of childbearing age
- ✕Pre-stroke handicap with mRS greater than 2
- ✕Diseases affecting motor function such as Parkinson's Disease or ALS
- ✕Participation in another investigational study within 30 days preceding and during present study
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Maraviroc for Stroke Recovery (MASTER): A Phase 2 Double-Blind Placebo-Controlled Randomized Clinical Trial
In Brief
A Phase 2 clinical trial evaluating Maraviroc and Mannitol for Ischemic Stroke and 2 related conditions. Currently recruiting, targeting 80 participants across 1 site.
Detailed Summary
MASTER is a single-center, patient and investigator-blinded, Randomized Controlled Trial (RCT) to compare the efficacy of Maraviroc, a C-C chemokine receptor 5 (CCR5) antagonist, against placebo regarding motor function and motor learning skills in the first 3 months after ischemic stroke.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIschemic Stroke, Stroke, Stroke Acute
CountriesSwitzerland
Collaborators--
Timeline
Phase 2Recruiting
202620272028
Enrollment StartJul 2025
First PostedJul 2025
TodayJul 2026
Primary CompletionDec 2027
First PostedJul 23, 2025
Enrollment StartJul 14, 2025
Primary CompletionDec 1, 2027
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 11 months agoPrimary completion in 1.4 years
Interventions
Maravirocdrug
Maraviroc (300mg) twice daily for 90 days
Mannitoldrug
Placebo intervention